

# Andrea Sboner

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/916599/andrea-sboner-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

29,601  
citations

56  
h-index

155  
g-index

155  
ext. papers

36,678  
ext. citations

14.4  
avg, IF

8.2  
L-index

#	Paper	IF	Citations
137	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 139-139	2.2	
136	Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. <i>Journal of Pathology</i> , <b>2022</b> ,	9.4	1
135	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6377	17.4	0
134	G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6662	17.4	3
133	High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study. <i>Blood</i> , <b>2021</b> , 138, 138-138	2.2	0
132	A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> , 54, 462-471	5.6	8
131	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 44	9.8	6
130	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	5
129	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , <b>2021</b> , 4, 785	6.7	0
128	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0
127	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 3372	17.4	3
126	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. <i>Translational Oncology</i> , <b>2021</b> , 14, 100944	4.9	2
125	Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. <i>Thyroid</i> , <b>2021</b> , 31, 589-595	6.2	4
124	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 786-793	6.2	3
123	Patient-derived xenografts and organoids model therapy response in prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 1117	17.4	18
122	MicroRNA-1205 Regulation of FRYL in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 647485	5.7	1
121	Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 66	6.2	2

120	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , <b>2021</b> , 26, e1971-e1981	5.7	1
119	Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. <i>Cell Reports</i> , <b>2021</b> , 36, 109625	10.6	4
118	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , <b>2020</b> , 22, 34-44	9.9	2
117	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , <b>2020</b> , 11, 5549	17.4	31
116	Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
115	Building an international consortium for tracking coronavirus health status. <i>Nature Medicine</i> , <b>2020</b> , 26, 1161-1165	50.5	16
114	Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 80	7.3	3
113	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1157-1164	6.1	23
112	Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis. <i>Cells</i> , <b>2020</b> , 9,	7.9	14
111	Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. <i>Nature Communications</i> , <b>2020</b> , 11, 1987	17.4	14
110	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1653-1668	15.9	56
109	Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8-8	2.2	
108	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 1535-1546	5	4
107	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , <b>2020</b> , 183, 197-210.e32	56.2	45
106	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 6195	17.4	6
105	PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6839-6851	12.9	22
104	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 121, 7-18	7.5	79
103	Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	8

102	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	15
101	FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. <i>Nature</i> , <b>2019</b> , 571, 408-412	50.4	81
100	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11428-11436	11.5	383
99	Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. <i>Gynecologic Oncology Reports</i> , <b>2019</b> , 28, 54-57	1.3	5
98	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	56
97	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. <i>Cancer Cell</i> , <b>2019</b> , 35, 603-617.e8	24.3	29
96	N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 3924-3940	15.9	55
95	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 272-272	2.2	5
94	Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 194-200	7.3	3
93	The genomic landscape of metastatic clear cell renal cell carcinoma (ccRCC) after treatment with systemic therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 675-675	2.2	
92	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 43-51	12.9	110
91	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 584-590	4	4
90	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. <i>Cancer</i> , <b>2018</b> , 124, 1008-1015	6.4	24
89	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 645-651	36.3	380
88	Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. <i>Journal of Pathology</i> , <b>2018</b> , 246, 244-253	9.4	21
87	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. <i>Nature</i> , <b>2018</b> , 560, 499-503	50.4	277
86	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , <b>2018</b> , 9, 2404	17.4	149
85	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 381-386	15.9	23

84	Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17039-e17039		
83	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1435-1435	2.2	1
82	Gene Fusions. <i>Molecular Pathology Library</i> , <b>2018</b> , 137-151		
81	BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	2
80	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	17
79	TBIO-15. UTILIZING A HISTOLOGY-SPECIFIC SEQUENCING ALGORITHM FOR PRECISION NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i183-i183	1	78
78	Integrative functional genomic analysis of human brain development and neuropsychiatric risks. <i>Science</i> , <b>2018</b> , 362,	33.3	277
77	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , <b>2018</b> , 72, 341-354.e6	17.6	38
76	CD38 is methylated in prostate cancer and regulates extracellular NAD. <i>Cancer &amp; Metabolism</i> , <b>2018</b> , 6, 13	5.4	18
75	Personalized and Cancer Models to Guide Precision Medicine. <i>Cancer Discovery</i> , <b>2017</b> , 7, 462-477	24.4	477
74	SPOP Mutation Drives Prostate Tumorigenesis InVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. <i>Cancer Cell</i> , <b>2017</b> , 31, 436-451	24.3	116
73	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. <i>Genome Biology</i> , <b>2017</b> , 18, 141	18.3	20
72	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	23
71	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6802-6811 <sup>2-9</sup>	12.9	50
70	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , <b>2017</b> , 32, 792-806.e7	24.3	39
69	Inherited determinants of early recurrent somatic mutations in prostate cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 48	17.4	16
68	The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2017</b> , 24, 513-519	8.6	66
67	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , <b>2016</b> , 48, 1490-1499	36.3	161

66	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. <i>Npj Genomic Medicine</i> , <b>2016</b> , 1,	6.2	51
65	A primer on precision medicine informatics. <i>Briefings in Bioinformatics</i> , <b>2016</b> , 17, 145-53	13.4	30
64	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 471-80	13.4	38
63	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , <b>2016</b> , 22, 298-305	50.5	775
62	The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. <i>Oncotarget</i> , <b>2016</b> , 7, 45597-45607	3.3	13
61	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , <b>2016</b> , 30, 563-577	24.3	256
60	MAGI3-AKT3 fusion in breast cancer amended. <i>Nature</i> , <b>2015</b> , 520, E11-2	50.4	20
59	ASEQ: fast allele-specific studies from next-generation sequencing data. <i>BMC Medical Genomics</i> , <b>2015</b> , 8, 9	3.7	38
58	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , <b>2015</b> , 163, 1011-25	56.2	1713
57	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , <b>2015</b> , 526, 453-7	50.4	144
56	SPOP mutation leads to genomic instability in prostate cancer. <i>ELife</i> , <b>2015</b> , 4,	8.9	110
55	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
54	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , <b>2015</b> , 1, 466-74	13.4	207
53	SPOP mutations in prostate cancer across demographically diverse patient cohorts. <i>Neoplasia</i> , <b>2014</b> , 16, 14-20	6.4	113
52	Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. <i>Genes Chromosomes and Cancer</i> , <b>2014</b> , 53, 183-93	5	117
51	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , <b>2014</b> , 46, 1227-32	36.3	348
50	Organoid cultures derived from patients with advanced prostate cancer. <i>Cell</i> , <b>2014</b> , 159, 176-187	56.2	847
49	MTSS1 is a metastasis driver in a subset of human melanomas. <i>Nature Communications</i> , <b>2014</b> , 5, 3465	17.4	43

48	Unraveling the clonal hierarchy of somatic genomic aberrations. <i>Genome Biology</i> , <b>2014</b> , 15, 439	18.3	61
47	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 5383	17.4	432
46	Epigenomic alterations in localized and advanced prostate cancer. <i>Neoplasia</i> , <b>2013</b> , 15, 373-83	6.4	59
45	Integrative annotation of variants from 1092 humans: application to cancer genomics. <i>Science</i> , <b>2013</b> , 342, 1235587	33.3	281
44	Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 1075-87	5	99
43	Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. <i>Neoplasia</i> , <b>2013</b> , 15, 1231-40	6.4	28
42	Punctuated evolution of prostate cancer genomes. <i>Cell</i> , <b>2013</b> , 153, 666-77	56.2	862
41	Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 775-84	5	349
40	Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 538-50	5	143
39	Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. <i>J Pathol</i> 2013; 230: 453-456. <i>Journal of Pathology</i> , <b>2013</b> , 231, 271	9.4	1
38	VAT: a computational framework to functionally annotate variants in personal genomes within a cloud-computing environment. <i>Bioinformatics</i> , <b>2012</b> , 28, 2267-9	7.2	55
37	An integrated encyclopedia of DNA elements in the human genome. <i>Nature</i> , <b>2012</b> , 489, 57-74	50.4	11449
36	Genomic analysis of the hydrocarbon-producing, cellulolytic, endophytic fungus <i>Ascocoryne sarcoides</i> . <i>PLoS Genetics</i> , <b>2012</b> , 8, e1002558	6	64
35	IQSeq: integrated isoform quantification analysis based on next-generation sequencing. <i>PLoS ONE</i> , <b>2012</b> , 7, e29175	3.7	5
34	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , <b>2011</b> , 1, 487-95	24.4	550
33	Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 98ra82	17.5	252
32	A user's guide to the encyclopedia of DNA elements (ENCODE). <i>PLoS Biology</i> , <b>2011</b> , 9, e1001046	9.7	1060
31	The genomic complexity of primary human prostate cancer. <i>Nature</i> , <b>2011</b> , 470, 214-20	50.4	984

30	The real cost of sequencing: higher than you think!. <i>Genome Biology</i> , <b>2011</b> , 12, 125	18.3	247
29	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. <i>Genome Research</i> , <b>2011</b> , 21, 56-67	9.7	156
28	Diverse protein kinase interactions identified by protein microarrays reveal novel connections between cellular processes. <i>Genes and Development</i> , <b>2011</b> , 25, 767-78	12.6	51
27	RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries. <i>Bioinformatics</i> , <b>2011</b> , 27, 281-3	7.2	89
26	Genomics and privacy: implications of the new reality of closed data for the field. <i>PLoS Computational Biology</i> , <b>2011</b> , 7, e1002278	5	56
25	Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays. <i>Nucleic Acids Research</i> , <b>2010</b> , 38, 3275-86	20.1	15
24	Integrative analysis of the <i>Caenorhabditis elegans</i> genome by the modENCODE project. <i>Science</i> , <b>2010</b> , 330, 1775-87	33.3	744
23	FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. <i>Genome Biology</i> , <b>2010</b> , 11, R104	18.3	121
22	Comparison and calibration of transcriptome data from RNA-Seq and tiling arrays. <i>BMC Genomics</i> , <b>2010</b> , 11, 383	4.5	88
21	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. <i>BMC Medical Genomics</i> , <b>2010</b> , 3, 8	3.7	169
20	Distinct genomic aberrations associated with ERG rearranged prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2009</b> , 48, 366-80	5	72
19	Robust-linear-model normalization to reduce technical variability in functional protein microarrays. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 5451-64	5.6	55
18	N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. <i>Neoplasia</i> , <b>2009</b> , 11, 804-11	6.4	92
17	The role of disorder in interaction networks: a structural analysis. <i>Molecular Systems Biology</i> , <b>2008</b> , 4, 179	12.2	167
16	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 569-76	7.5	32
15	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 815-25	9.7	251
14	UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. <i>Oncogene</i> , <b>2007</b> , 26, 2136-40	9.2	61
13	Comparing classical pathways and modern networks: towards the development of an edge ontology. <i>Trends in Biochemical Sciences</i> , <b>2007</b> , 32, 320-31	10.3	49



12	Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 10296-303	10.1	64
11	UbcH10 is overexpressed in malignant breast carcinomas. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2729-357.5		56
10	TMABoost: an integrated system for comprehensive management of tissue microarray data. <i>IEEE Transactions on Information Technology in Biomedicine</i> , <b>2006</b> , 10, 19-27		17
9	An automated procedure to properly handle digital images in large scale tissue microarray experiments. <i>Computer Methods and Programs in Biomedicine</i> , <b>2005</b> , 79, 197-208	6.9	13
8	Clinical validation of an automated system for supporting the early diagnosis of melanoma. <i>Skin Research and Technology</i> , <b>2004</b> , 10, 184-92	1.9	13
7	A multiple classifier system for early melanoma diagnosis. <i>Artificial Intelligence in Medicine</i> , <b>2003</b> , 27, 29-44	7.4	75
6	Automatic model selection in cost-sensitive boosting. <i>Information Fusion</i> , <b>2003</b> , 4, 3-10	16.7	14
5	Analysis of user-satisfaction with the use of a teleconsultation system in oncology. <i>Informatics for Health and Social Care</i> , <b>2003</b> , 28, 73-84		17
4	Combining Supervised and Unsupervised Methods to Support Early Diagnosis of Hepatocellular Carcinoma. <i>Lecture Notes in Computer Science</i> , <b>2003</b> , 239-243	0.9	
3	Role of Specialized Composition of SWI/SNF Complexes in Prostate Cancer Lineage Plasticity		1
2	Novel patterns of complex structural variation revealed across thousands of cancer genome graphs		8
1	SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape		2